Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has shared an update.
Shanghai HeartCare Medical Technology Corporation Limited reported a significant financial turnaround for the first half of 2025, with a 44.4% increase in revenue to RMB185.5 million and a net profit of RMB50.9 million, reversing a loss from the previous year. This improvement is attributed to the successful launch of new hemorrhagic stroke treatment devices, increased sales of existing products, and effective cost control measures. The company is also enhancing its product offerings with new approvals and expanding its international presence through product registrations in multiple countries.
The most recent analyst rating on (HK:6609) stock is a Hold with a HK$54.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a company in the medical technology industry, focusing on the development and sale of neuro-intervention treatment devices. Its primary products include devices for the treatment of hemorrhagic and ischemic strokes, with a market focus on providing innovative and differentiated treatment solutions.
Average Trading Volume: 184,841
Technical Sentiment Signal: Buy
Current Market Cap: HK$2B
See more data about 6609 stock on TipRanks’ Stock Analysis page.